254 related articles for article (PubMed ID: 11063646)
41. Platinum - sensitive relapsed epithelial ovarian cancer: not all the patients benefit from reinduction with carboplatin and paclitaxel.
Milović-Kovačević M; Stamatovic L; Popov I; Radošević-Jelić L; Kezic I
Med Sci Monit; 2010 Nov; 16(11):CR549-54. PubMed ID: 20980960
[TBL] [Abstract][Full Text] [Related]
42. Intraperitoneal interferon-alpha in residual ovarian carcinoma: a phase II gynecologic oncology group study.
Berek JS; Markman M; Stonebraker B; Lentz SS; Adelson MD; DeGeest K; Moore D
Gynecol Oncol; 1999 Oct; 75(1):10-4. PubMed ID: 10502418
[TBL] [Abstract][Full Text] [Related]
43. Weekly paclitaxel in heavily pretreated ovarian cancer patients: does this treatment still provide further advantages?
Miolo G; Bidoli E; Lombardi D; Santeufemia DA; Capobianco G; Dessole F; Scalone S; Spazzapan S; Sorio R; Tabaro G; Veronesi A
Arch Gynecol Obstet; 2012 Feb; 285(2):499-503. PubMed ID: 21735184
[TBL] [Abstract][Full Text] [Related]
44. Platinum compounds and paclitaxel in advanced epithelial ovarian cancer.
Gadducci A; Brunetti I; Cosio S; Giannessi PG; Genazzani AR; Conte P
Anticancer Res; 1997; 17(6D):4703-8. PubMed ID: 9494592
[TBL] [Abstract][Full Text] [Related]
45. Improved overall survival with 12 cycles of single-agent paclitaxel maintenance therapy following a complete response to induction chemotherapy in advanced ovarian carcinoma.
Abaid LN; Goldstein BH; Micha JP; Rettenmaier MA; Brown JV; Markman M
Oncology; 2010; 78(5-6):389-93. PubMed ID: 20798562
[TBL] [Abstract][Full Text] [Related]
46. Second-line therapy with paclitaxel and carboplatin for recurrent disease following first-line therapy with paclitaxel and platinum in ovarian or peritoneal carcinoma.
Rose PG; Fusco N; Fluellen L; Rodriguez M
J Clin Oncol; 1998 Apr; 16(4):1494-7. PubMed ID: 9552057
[TBL] [Abstract][Full Text] [Related]
47. Feasibility of extension of platinum-free interval with weekly bolus topotecan and subsequent platinum retreatment outcomes in recurrent ovarian cancer.
Bryant CS; Kumar S; Spannuth W; Shah JP; Munkarah AR; Deppe G; Alvarez RD; Morris RT
Arch Gynecol Obstet; 2011 Feb; 283(2):361-7. PubMed ID: 20383771
[TBL] [Abstract][Full Text] [Related]
48. [Chemotherapy for recurrent ovarian cancer].
Nishimura H; Imamura K; Chang C
Gan To Kagaku Ryoho; 1996 Aug; 23(9):1124-8. PubMed ID: 8751798
[TBL] [Abstract][Full Text] [Related]
49. Treatment of refractory and recurrent ovarian cancer.
Alberts DS
Semin Oncol; 1999 Feb; 26(1 Suppl 1):8-14. PubMed ID: 10071969
[TBL] [Abstract][Full Text] [Related]
50. Single agent paclitaxel in resistant and relapsed epithelial ovarian cancer after first-line platinum-based chemotherapy--experience in an Asian population.
Tay SK; Thilagam MD
Ann Acad Med Singap; 1998 Sep; 27(5):645-9. PubMed ID: 9919333
[TBL] [Abstract][Full Text] [Related]
51. Phase 2 trial of moderately high dose single agent mitoxantrone in platinum and paclitaxel-refractory ovarian cancer.
Markman M; Lichtman SM; Homesley H; Kennedy A; Webster K; Ernst S; Omura G; Belinson J
Gynecol Oncol; 1998 Jul; 70(1):123-6. PubMed ID: 9698488
[TBL] [Abstract][Full Text] [Related]
52. [China-made paclitaxel in the treatment of advanced ovarian cancer: a clinical analysis of 32 cases].
Liu L; Hong W; Zhang R
Zhonghua Fu Chan Ke Za Zhi; 1997 Apr; 32(4):222-5. PubMed ID: 9596903
[TBL] [Abstract][Full Text] [Related]
53. Lack of effective systemic therapy for recurrent clear cell carcinoma of the ovary.
Crotzer DR; Sun CC; Coleman RL; Wolf JK; Levenback CF; Gershenson DM
Gynecol Oncol; 2007 May; 105(2):404-8. PubMed ID: 17292461
[TBL] [Abstract][Full Text] [Related]
54. Paclitaxel in patients with platinum-resistant ovarian cancer: a selected review of literature and clinical experience.
Kudelka AP; Tresukosol D; Gonzalez de Leon C; Termrungruanglert W; Edwards CL; Freedman RS; Tornos C; Kavanagh JJ
J Med Assoc Thai; 1996 Apr; 79(4):240-5. PubMed ID: 8708510
[TBL] [Abstract][Full Text] [Related]
55. [Favorable results of paclitaxel (Taxol) in patients with ovary carcinoma pretreated with platinum].
Hoekman K; Huijskes RV; Burger CW; Verheijen RH; Pinedo HM; Vermorken JB
Ned Tijdschr Geneeskd; 1995 Feb; 139(6):272-8. PubMed ID: 7862216
[TBL] [Abstract][Full Text] [Related]
56. Phase II activity of belinostat (PXD-101), carboplatin, and paclitaxel in women with previously treated ovarian cancer.
Dizon DS; Damstrup L; Finkler NJ; Lassen U; Celano P; Glasspool R; Crowley E; Lichenstein HS; Knoblach P; Penson RT
Int J Gynecol Cancer; 2012 Jul; 22(6):979-86. PubMed ID: 22694911
[TBL] [Abstract][Full Text] [Related]
57. Hexamethylmelamine as a single second-line agent in ovarian cancer: follow-up report and review of the literature.
Manetta A; Tewari K; Podczaski ES
Gynecol Oncol; 1997 Jul; 66(1):20-6. PubMed ID: 9234915
[TBL] [Abstract][Full Text] [Related]
58. Randomized controlled trial of single-agent paclitaxel versus cyclophosphamide, doxorubicin, and cisplatin in patients with recurrent ovarian cancer who responded to first-line platinum-based regimens.
Cantù MG; Buda A; Parma G; Rossi R; Floriani I; Bonazzi C; Dell'Anna T; Torri V; Colombo N
J Clin Oncol; 2002 Mar; 20(5):1232-7. PubMed ID: 11870165
[TBL] [Abstract][Full Text] [Related]
59. Neoadjuvant intraperitoneal chemotherapy with paclitaxel for the radical surgical treatment of peritoneal carcinomatosis in ovarian cancer: a prospective pilot study.
Muñoz-Casares FC; Rufián S; Arjona-Sánchez Á; Rubio MJ; Díaz R; Casado Á; Naranjo Á; Díaz-Iglesias CJ; Ortega R; Muñoz-Villanueva MC; Muntané J; Aranda E
Cancer Chemother Pharmacol; 2011 Jul; 68(1):267-74. PubMed ID: 21499894
[TBL] [Abstract][Full Text] [Related]
60. Is stabilization of disease a useful indicator for survival in second-line treatment of ovarian carcinoma pre-treated with Paclitaxel-Platinum?
Gronlund B; Høgdall C; Christensen IJ; Engelholm SA; Hansen HH
Gynecol Oncol; 2004 Aug; 94(2):409-15. PubMed ID: 15297181
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
